Document is current
Any future updates will be listed below
-
Authors
Kloots, Iris S. H. https://orcid.org/0000-0001-9181-1359
Slootbeek, Peter H. J. https://orcid.org/0000-0002-5635-919X
Tolmeijer, Sofie H.
van Wilpe, Sandra
Smits, Minke
van Helvert, Sjoerd
Kroeze, Leonie I. https://orcid.org/0000-0002-2666-1742
van Ipenburg, Jolique A.
Grünberg, Katrien
Kets, C. Marleen
Ligtenberg, Marjolijn J. L. https://orcid.org/0000-0003-1290-1474
Nagarajah, James
Fütterer, Jurgen
van Dodewaard, Joyce M.
van Voorthuizen, Theo
Terheggen, Frederiek
Smilde, Tineke J.
Schalken, Jack A. https://orcid.org/0000-0001-8274-7797
van Oort, Inge M.
Bloemendal, Haiko J.
Gerritsen, Winald R.
Mehra, Niven https://orcid.org/0000-0002-4794-1831
,
van Dodewaard, Joyce M.
van Voorthuizen, Theo
van Oort, Inge M.
-
Funding
Funding for this research was provided by:
Betaalbaar beter; Radboud Oncologie Fonds - ROF1907; Paul Speth Foundation
- License Information
-
More Information
Article History
Received: 3 December 2024
Revised: 5 August 2025
Accepted: 13 October 2025
First Online: 31 October 2025
Competing interests
: MJL received consulting fees from GlaxoSmithKline B.V., Janssen-Cilag B.V., AstraZeneca; received honoraria for lectures: AstraZeneca, Janssen, Roche, MSD, Pfizer. All payments to Radboudumc. WRG is a member of the advisory boards of Astellas, Coretag holding AG, Merck Sharp and Dohme, and Novartis; received personal fees for coaching activities by Bayer; and is member of the board of directors of ORCA therapeutic B.V. NM received consultancy fees from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Johnson & Johnson, Merck Sharp and Dohme, and Pfizer; and research funding (all paid to the institution) from Astellas Pharma, AstraZeneca/Merck, Bristol Myers Squibb Foundation, and Janssen-Cilag. All other authors declare that they have no competing interests.
: The trial was conducted in accordance with the principles of the Declaration of Helsinki and classified by the medical ethical committee of “Commissie Mensgebonden Onderzoek” (CMO) regio Arnhem-Nijmegen. No ethics approval was needed for this study. All patients provided written informed consent. The study is registered in ClinicalTrials.gov under the number NCT04746300.
: Not applicable.
